Etomidate Versus Propofol in CABG Surgery
- Registration Number
- NCT06068764
- Lead Sponsor
- Hartford Hospital
- Brief Summary
The objective of this single-blinded randomized controlled interventional clinical trial is to learn about the efficacy and long-term safety of etomidate compared to propofol as an anesthesia induction agent in patients undergoing coronary artery bypass graft (CABG) surgery. The primary aim of this study is to determine whether patients receiving etomidate or propofol exhibit similar requirements for vasopressor or ionotropic agents during both the intraoperative and postoperative periods.
To achieve this goal, participants who are scheduled for CABG surgery will be randomly assigned to receive either etomidate or propofol as the principal hypnotic agent. The researchers will then compare the effects of these two anesthesia induction agents on various factors, including the need for hemodynamic support, hemodynamic stability, duration of mechanical ventilation, length of stay in the intensive care unit (ICU), and overall hospital length of stay. Additionally, they will assess whether there are disparities in mortality rates and readmission rates within a 6-month timeframe after the surgery.
By comparing the outcomes between the two groups, the study aims to provide valuable insights into the potential differences in vasopressor or ionotropic agent requirements between etomidate and propofol. This information can help inform clinical decision-making and potentially optimize anesthesia management strategies for patients undergoing CABG surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
- Patients scheduled for elective open coronary arteries bypass graft CABG surgery
- Patients with American Society of Anesthesiology (ASA) physical status score I- IV
- Patients with the ability to speak and read both English and Spanish
- Emergency CABG surgery, STAT cases, and add-on cases.
- Refusal or lack of providing the study consent
- Patients with a known current adrenocortical insufficiency
- A patient who is presenting with any kind of shock, (e.g. septic, hypovolemic, cardiogenic, etc.)
- Patients with chronic steroid use (defined as the use of glucocorticoids within 6 months preoperatively)
- Patients with a known allergy to etomidate or propofol.
- Patients with a known seizure disorder.
- Patients who are enrolled in other clinical research studies that can compete with this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Propofol Propofol Propofol as the principal hypnotic agent in a single bolus dose of 50mg of propofol along with 250 mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine. Etomidate Etomidate Etomidate as the principal hypnotic agent in a single bolus dose of 0.2-0.3 mg/kg along with 250mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
- Primary Outcome Measures
Name Time Method Vasopressors dose expressed by Noradrenaline Equivalent dose [μg/kg/min] 30 minutes after induction, last 30 minutes of post bypass period, and first 24 hours post procedure. Vasopressor requirements will be expressed as Noradrenaline Equivalent dose using the formula of (NEq \[μg/kg/min\] = norepinephrine + epinephrine + phenylephrine/10 + dopamine/100 + vasopressin\*2.5), this will be measured during three periods of time: Intraoperatively during the first 30 minutes post induction (as a reflection of the impact of induction on hemodynamics), intraoperatively during the last 30 minutes of the post bypass period, and for the first 24 hours post procedure.
- Secondary Outcome Measures
Name Time Method ICU length of stay 3 days ICU length of stay will be calculated in hours using the ICU data from EPIC.
The number of incidences of shock First 24 hours post anesthesia The incidence of both vasogenic and cardiogenic shocks will be determined intraoperatively and postoperatively using the Mean Arterial Pressure (MAP), Central Venous Pressure (CVP), Cardiac Output (CO), and Systemic Vascular Resistance (SVR).
Vasogenic shock (defined as a MAP \< 60 mmHg with normal CO (\>2.0 L/min) and low SVR (\< 900 dynes/sec).
Cardiogenic shock (defined as hypotension with MAP \< 60 mmHg, low CO (\<2.0 L/min), and normal SVR range (900-1400 dynes/sec).Time to extubation and end of mechanical ventilation until extubation, assessed as 6 hours Time to extubation, the standard of care is usually within 6 hours of arriving to the unit.
Hospital length of stay 7 days Hospital length of stay will be calculated in hours from the date and time of admission and discharge, from EPIC.
Hospital Readmissions 6 months In the 6th month after surgery, a retrospective safety checkup will be done, using EPIC chart review, to assess the number of readmissions.
Incidence of Death 6 months In the 6th month after surgery, a retrospective safety checkup will be done, using EPIC chart review, to assess the number of deaths if any.
Trial Locations
- Locations (1)
Hartford Hospital
🇺🇸Hartford, Connecticut, United States